{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:19:08Z","timestamp":1791206348864,"version":"4.1.0"},"reference-count":0,"publisher":"Georg Thieme Verlag KG","issue":"06","funder":[{"name":"Deutsche Forschungsgemeinschaft (DFG)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2008]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Lenalidomide, a derivate of thalidomide, has recently been approved in Europe for the treatment of patients with multiple myeloma. Although the substance has a better effect\/side-effect profile, especially with regard to teratogenicity and neurotoxicity, the rate of therapy-induced thrombosis seems comparable to thalidomide. The observed thromboembolic events were accompanied with a high rate of deleterious pulmonary embolism. Interestingly, the substances alone are not thrombogenic but combination with anthracyclines, dexamethasone or erythropesis-stimulating factors increases the risk considerably. As up to one third of patients treated with such combinations are affected, antithrombotic co-medication is highly recommended. This review elucidates the complex interactions between an activated coagulation-system in myeloma patients and the molecular effects of these drugs. This perception is important to choose the proper prophylactic co-medication without increasing the risk of bleeding, especially in first-line treatment, patients with high paraprotein-levels, or thrombopenia, either therapy-induced or due to bone-marrow infiltration.<\/jats:p>","DOI":"10.1160\/th08-01-0009","type":"journal-article","created":{"date-parts":[[2008,5,13]],"date-time":"2008-05-13T07:33:25Z","timestamp":1210664005000},"page":"1001-1007","source":"Crossref","is-referenced-by-count":16,"title":["Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates"],"prefix":"10.1160","volume":"99","author":[{"given":"Frank","family":"Gieseler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2017,11,27]]},"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1160\/TH08-01-0009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T06:24:45Z","timestamp":1521527085000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1160\/TH08-01-0009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008]]},"references-count":0,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2017,11,23]]},"published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1160\/th08-01-0009","relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008]]}}}